The Swiss pharmaceutical giant Roche has unveiled late-stage clinical data for fenebrutinib, an experimental therapy designed to reshape the treatment landscape for multiple sclerosis. According to the company, three Phase 3 trials demonstrate the drug’s ability to significantly reduce relapse rates and impede the progressive disability that characterizes the autoimmune condition. These results provide the foundation for Roche’s upcoming bid for regulatory approval, positioning the drug as a potentially potent tool for patients with few remaining options.
However, the clinical success is tempered by a familiar and formidable shadow: liver toxicity. Analysts have noted worrying safety signals that echo the regulatory hurdles that stalled previous efforts in this specific drug class. The Food and Drug Administration has historically maintained a high threshold for safety in MS treatments, notably rejecting a similar therapy from Sanofi due to concerns over drug-induced liver injury.
The gravity of these concerns was heightened by the disclosure of two drug-related deaths among trial participants. While Roche remains confident in the drug’s benefit-risk profile, the fatalities introduce a layer of complexity to the regulatory review process. For regulators, the decision will hinge on whether fenebrutinib’s clinical efficacy justifies the systemic risks, a calculation that remains the most precarious bottleneck in modern drug development.
With reporting from STAT News.
Source · STAT News (Biotech)
